TP53 co-mutations in advanced lung adenocarcinoma: comparative bioinformatic analyses suggest ambivalent character on overall survival alongside KRAS, STK11 and KEAP1 mutations

Also consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1. TP53 Mutations in Nonsmall Cell Lung Cancer· 2011 · 394 citations
2. CURRENT THERAPEUTIC STRATEGIES AND CHALLENGES IN NSCLC TREATMENT: A COMPREHENSIVE REVIEW· 2022 · 31 citations
3. Abstract CT084: Relationship between <i>STK11</i> and <i>KEAP1</i> mutational status and efficacy in KEYNOTE-042: pembrolizumab monotherapy versus platinum-based chemotherapy as first-line therapy for PD-L1-positive advanced NSCLC· 2020 · 43 citations
4. Spectrum of Lung Adenocarcinoma· 2018 · 199 citations
5. KEAP1-driven co-mutations in lung adenocarcinoma unresponsive to immunotherapy despite high tumor mutational burden· 2020 · 223 citations